Syntermed's NeuroQ™ 3.7 for SPECT Brain Imaging Announced at RSNA

Share Article

In 2013 Syntermed, Inc. received 510K clearance from the Food and Drug Administration for NeuroQ™ 3.6, software used in nuclear medicine clinics for PET-FDG brain scans plus an additional clearance for its amyloid brain uptake imaging application. As a work in progress, that 510K clearance extends to Syntermed’s newest nuclear medicine software, NeuroQ 3.7 for SPECT brain imaging quantification.

Dementia SPECT brain scans

Syntermed, NeuroQ 3.7 SPECT brain imaging software

NeuroQ is well established and being utilized in nuclear medicine labs worldwide for the quantitation of PET- FDG and Amyloid brain imaging studies, so adding SPECT was a logical next step. -- Michael Lee, CEO, Syntermed, Inc.

Past News Releases


Syntermed, Inc. announces availability for its newest NeuroQ™ SPECT brain imaging software product for the U.S. nuclear medicine market at the RSNA annual meeting November 29-December 4 in Chicago, IL.

“NeuroQ is well established and being utilized in nuclear medicine labs worldwide for the quantitation of PET- FDG and Amyloid brain imaging studies, so adding SPECT was a logical next step,” announced Michael Lee, CEO, Syntermed, Inc. “Radiologists and their departments will now have a single platform with NeuroQ 3.7 capable of supporting the most relevant functional imaging modalities for differential diagnosis of dementia.”

“Initial validation of NeuroQ 3.7 for SPECT analysis has demonstrated accurate results reducing the variability of the final results,” added Ken Van Train, President, Syntermed. “NeuroQ 3.7 uses its standardized region of interest (ROI) method to analyze the distribution for SPECT, plus the interface functions and reporting output shall be the same as with FDG and Amyloid, so the learning curve should be very quick.”

Within this area of imaging, NeuroQ software analyzes hard to detect differences within the brain study and automatically calculates the values within pre-defined regions of the brain to assist with the final interpretation of the images by the nuclear medicine specialist. NeuroQ also benefits the clinician and patient by being able to perform side-by-side comparable analysis from two studies of the same patient done at two points in time. “The differential diagnosis of dementia is complex and being able to quantify disease progression is very important to the clinicians using NeuroQ in their nuclear medicine labs,” adds Lee.

Dementia is not a catch-all answer for the aging process. In fact it’s estimated by various studies that up to 5 percent of Americans diagnosed with some type of dementia actually have a treatable condition called normal pressure hydrocephalus. The symptoms are very similar to dementia and there are medical procedures that can correct and reverse the condition. And of all the many type of dementia, of which Alzheimers accounts for two-thirds followed by vascular dementia, specific medical treatments may slow the progression of the disease and provide a great quality of life when properly diagnosed and diagnosed early.

Dementia is a worldwide medical problem. In the UK, BBC Science news desk recently reported less than half of adults with dementia-type symptoms have received a definitive diagnosis. Currently approximately 800,000 adults in the UK have been diagnosed with some type of dementia and of that number 17,000 are under the age of 65. The report cites the lack of support systems and specially trained clinicians.

“Our belief is that in this era of personalized medicine, the physician and nuclear medicine lab technologists need access to tools that can enhance workflow and improve quantitative analysis of the final diagnostic interpretation,” says Lee. “For example, Syntermed’s NeuroQ amyloid brain uptake application is a niche application, not every lab performs these studies, but those that do should have the flexibility within their NeuroQ software to analyze the distribution of FDG and amyloid PET tracers in the brain and calculate the density of the beta-amyloid neuritic plaque with efficiency and a high degree of accuracy.”

About Syntermed, Inc.: an Atlanta-based imaging and informatics company supporting SPECT and PET imaging for heart and brain studies with quantification, reporting, and clinical decision support software.

Syntermed signature products: NeuroQ for PET-FDG and Amyloid brain imaging, and now NeuroQ SPECT brain imaging software, used in the differential diagnosis of dementia; Emory Toolbox, now in its fourth generation, is utilized by nuclear cardiology labs worldwide; SyncTool™ for advanced phase analysis imaging studies of left ventricle dyssynchrony.

A full snapshot of the Syntermed products can be found at the RSNA digital profile website.

Michael Lee, CEO, and Ken Van Train, President will be available at the RSNA meeting, Syntermed Booth 7711 (North Hall B) to provide additional details about Syntermed's pipeline products and market expansion.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Roberts
Visit website